Jinghua Pharmaceutical Group Co., Ltd. (SHE:002349)

China flag China · Delayed Price · Currency is CNY
6.53
-0.02 (-0.31%)
Jun 10, 2026, 3:04 PM CST
Market Cap5.41B -6.4%
Revenue (ttm)1.48B +5.6%
Net Income222.94M +9.4%
EPS0.27 +8.7%
Shares Out 828.87M
PE Ratio24.01
Forward PEn/a
Dividend0.09 (1.37%)
Ex-Dividend DateMay 29, 2026
Volume8,179,500
Open6.54
Previous Close6.55
Day's Range6.40 - 6.66
52-Week Range6.40 - 8.45
Beta0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About SHE:002349

Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China. [Read more]

Sector Healthcare
Founded 1957
Employees 1,462
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002349
Full Company Profile

Financial Performance

In 2025, SHE:002349's revenue was 1.46 billion, an increase of 4.13% compared to the previous year's 1.40 billion. Earnings were 219.28 million, an increase of 3.12%.

Financial Statements